statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atara Biotherapeutics (ATRA Research Report) and Embecta Corporation...

Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Atara Biotherapeutics price target lowered by $2.50 at Stifel, here's why

StockNews.com cut shares of Atara Biotherapeutics (NASDAQ:ATRA - Free Report) from a hold rating to a sell rating in a report released on Thursday morning. Atara Biotherapeutics Stock Down 0.9...

StockNews.com Lowers Atara Biotherapeutics (NASDAQ:ATRA) to Sell

Analysts fell to the sidelines weighing in on Affimed (AFMD Research Report) and Atara Biotherapeutics (ATRA Research Report) with neutral rati...

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)

Atara Biotherapeutics ( NASDAQ:ATRA ) Full Year 2023 Results Key Financial Results Net loss: US$276.1m (loss widened by...

Atara Biotherapeutics Full Year 2023 Earnings: Revenues Disappoint

StockNews.com lowered shares of Atara Biotherapeutics (NASDAQ:ATRA  Free Report) from a hold rating to a sell rating in a research note issued to investors on Thursday.
Atara Biotherapeutics...

Atara Biotherapeutics (NASDAQ:ATRA) Cut to Sell at StockNews.com

Atara Biotherapeutics (ATRA) just unveiled an announcement. Eric Dobmeier, a board member of Atara Biotherapeutics, Inc., has decided not to seek r...

Atara Biotherapeutics Board Member Decides Not to Seek Re-Election

Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Accounting & Financial Operations category. Atara Biotherapeutics Inc. faces subs...

Atara Biotherapeutics' Profitability Hinges on Partners' Success with Ebvallo Amid Market Challenges

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Volume	255,363.00
52-Wk High	$3.02
52-Wk Low	$0.1986

ATRA Atara Biotherapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals